 Thomas Beresford
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 18 | 2023 | 765 | 3.610 |
Why?
| | Alcohol Deterrents | 6 | 2007 | 17 | 1.420 |
Why?
| | Disulfiram | 6 | 2007 | 14 | 1.420 |
Why?
| | Immunosuppressive Agents | 4 | 2019 | 858 | 1.290 |
Why?
| | Calcineurin | 3 | 2019 | 98 | 1.110 |
Why?
| | Cyclosporine | 3 | 2018 | 263 | 1.100 |
Why?
| | Cocaine-Related Disorders | 4 | 2017 | 108 | 1.020 |
Why?
| | Alcohol Drinking | 5 | 2018 | 765 | 0.960 |
Why?
| | Defense Mechanisms | 3 | 2014 | 24 | 0.950 |
Why?
| | Alcohol-Related Disorders | 4 | 2014 | 118 | 0.880 |
Why?
| | Antipsychotic Agents | 3 | 2017 | 195 | 0.820 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2023 | 176 | 0.790 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2018 | 89 | 0.790 |
Why?
| | Aripiprazole | 3 | 2017 | 17 | 0.780 |
Why?
| | Cost of Illness | 2 | 2014 | 277 | 0.750 |
Why?
| | Liver Transplantation | 4 | 2018 | 833 | 0.660 |
Why?
| | Schizophrenia | 2 | 2017 | 431 | 0.600 |
Why?
| | Nervous System Diseases | 2 | 2019 | 251 | 0.590 |
Why?
| | Perphenazine | 1 | 2017 | 1 | 0.580 |
Why?
| | Dopamine Agents | 1 | 2017 | 16 | 0.570 |
Why?
| | Craving | 1 | 2017 | 40 | 0.560 |
Why?
| | Brain Injuries, Traumatic | 1 | 2022 | 341 | 0.540 |
Why?
| | Ego | 2 | 2006 | 11 | 0.500 |
Why?
| | Jurisprudence | 2 | 2005 | 14 | 0.460 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2005 | 40 | 0.430 |
Why?
| | Hepatitis C | 3 | 2007 | 243 | 0.430 |
Why?
| | Cannabinoids | 1 | 2015 | 154 | 0.420 |
Why?
| | Ethanol | 4 | 2023 | 591 | 0.420 |
Why?
| | Psychotherapy | 1 | 2014 | 158 | 0.400 |
Why?
| | Models, Psychological | 1 | 2014 | 309 | 0.390 |
Why?
| | Brain | 2 | 2015 | 2673 | 0.370 |
Why?
| | Patient Compliance | 3 | 2007 | 565 | 0.370 |
Why?
| | Hippocampus | 2 | 2006 | 873 | 0.360 |
Why?
| | Tacrolimus | 1 | 2012 | 193 | 0.350 |
Why?
| | Sirolimus | 1 | 2012 | 270 | 0.340 |
Why?
| | Neurology | 1 | 2010 | 103 | 0.320 |
Why?
| | Cannabis | 1 | 2015 | 462 | 0.300 |
Why?
| | Inflammation | 1 | 2019 | 2750 | 0.300 |
Why?
| | Food Handling | 3 | 2016 | 60 | 0.290 |
Why?
| | Humans | 39 | 2023 | 129626 | 0.280 |
Why?
| | Stearates | 1 | 2007 | 1 | 0.270 |
Why?
| | Palmitic Acids | 1 | 2007 | 9 | 0.270 |
Why?
| | Oleic Acids | 1 | 2007 | 10 | 0.270 |
Why?
| | Double-Blind Method | 4 | 2022 | 1875 | 0.270 |
Why?
| | Behavior, Addictive | 1 | 2007 | 81 | 0.270 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2006 | 10 | 0.270 |
Why?
| | Sick Role | 1 | 2006 | 18 | 0.260 |
Why?
| | Bipolar Disorder | 5 | 2006 | 235 | 0.260 |
Why?
| | Serum Albumin | 1 | 2007 | 149 | 0.250 |
Why?
| | Valproic Acid | 2 | 2022 | 47 | 0.250 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 540 | 0.250 |
Why?
| | Mental Disorders | 1 | 2014 | 1034 | 0.240 |
Why?
| | Depressive Disorder, Major | 2 | 2020 | 345 | 0.240 |
Why?
| | Anxiety Disorders | 2 | 2005 | 353 | 0.230 |
Why?
| | Hydrocortisone | 1 | 2006 | 306 | 0.220 |
Why?
| | Administration, Sublingual | 1 | 2004 | 10 | 0.220 |
Why?
| | Mood Disorders | 1 | 2005 | 121 | 0.220 |
Why?
| | Male | 25 | 2018 | 63670 | 0.220 |
Why?
| | Middle Aged | 19 | 2017 | 31136 | 0.210 |
Why?
| | Quinolones | 1 | 2005 | 127 | 0.210 |
Why?
| | Teaching | 1 | 2005 | 217 | 0.210 |
Why?
| | Cocaine | 2 | 2009 | 149 | 0.210 |
Why?
| | Diagnosis, Dual (Psychiatry) | 2 | 2017 | 36 | 0.200 |
Why?
| | Anticonvulsants | 1 | 2005 | 209 | 0.200 |
Why?
| | Piperazines | 1 | 2005 | 340 | 0.200 |
Why?
| | Psychiatry | 1 | 2005 | 179 | 0.200 |
Why?
| | Cheese | 3 | 2016 | 5 | 0.200 |
Why?
| | Postoperative Care | 1 | 2004 | 241 | 0.200 |
Why?
| | Signal Transduction | 1 | 2015 | 4931 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2011 | 0.190 |
Why?
| | Irritable Mood | 1 | 2022 | 50 | 0.180 |
Why?
| | Learning | 1 | 2005 | 407 | 0.180 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 617 | 0.180 |
Why?
| | Adult | 18 | 2017 | 35599 | 0.180 |
Why?
| | Depressive Disorder, Treatment-Resistant | 1 | 2020 | 5 | 0.180 |
Why?
| | Prognosis | 3 | 2018 | 3774 | 0.180 |
Why?
| | Brain Injuries | 1 | 2005 | 466 | 0.170 |
Why?
| | Lactobacillus helveticus | 2 | 2009 | 2 | 0.160 |
Why?
| | Animals | 8 | 2019 | 35391 | 0.160 |
Why?
| | Antidepressive Agents | 2 | 2020 | 229 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2006 | 533 | 0.160 |
Why?
| | DNA Transposable Elements | 2 | 2009 | 119 | 0.150 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 55 | 0.150 |
Why?
| | Alcohol Abstinence | 1 | 2018 | 13 | 0.150 |
Why?
| | Binge-Eating Disorder | 1 | 2018 | 16 | 0.150 |
Why?
| | Injections, Intraperitoneal | 1 | 2018 | 112 | 0.140 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 5455 | 0.140 |
Why?
| | Neuroimmunomodulation | 1 | 2018 | 69 | 0.140 |
Why?
| | Female | 20 | 2017 | 68734 | 0.140 |
Why?
| | Brain Chemistry | 1 | 2018 | 118 | 0.140 |
Why?
| | Medical History Taking | 1 | 2018 | 118 | 0.140 |
Why?
| | Bupropion | 1 | 2017 | 40 | 0.140 |
Why?
| | Drug Substitution | 1 | 2017 | 51 | 0.140 |
Why?
| | Depression | 1 | 2006 | 1317 | 0.140 |
Why?
| | Comorbidity | 4 | 2017 | 1547 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2018 | 264 | 0.130 |
Why?
| | Volatile Organic Compounds | 1 | 2016 | 57 | 0.130 |
Why?
| | Internship and Residency | 1 | 2005 | 1050 | 0.120 |
Why?
| | Community Mental Health Services | 2 | 2006 | 89 | 0.120 |
Why?
| | Probability | 2 | 2006 | 306 | 0.120 |
Why?
| | Severity of Illness Index | 1 | 2023 | 2739 | 0.120 |
Why?
| | Patient Selection | 1 | 2018 | 661 | 0.110 |
Why?
| | Health Facilities | 1 | 2014 | 80 | 0.110 |
Why?
| | Cooperative Behavior | 2 | 2006 | 433 | 0.100 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2006 | 248 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2022 | 10219 | 0.100 |
Why?
| | Veterans | 4 | 2017 | 1375 | 0.100 |
Why?
| | Hospitals, Veterans | 4 | 2006 | 243 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2006 | 4894 | 0.100 |
Why?
| | United States | 7 | 2017 | 13871 | 0.090 |
Why?
| | Self Administration | 1 | 2012 | 120 | 0.090 |
Why?
| | Sucrose | 1 | 2012 | 99 | 0.090 |
Why?
| | Neoplasms | 1 | 2006 | 2455 | 0.090 |
Why?
| | Bacterial Typing Techniques | 2 | 2009 | 43 | 0.090 |
Why?
| | Mice | 3 | 2018 | 16961 | 0.090 |
Why?
| | Patient Care Team | 2 | 2006 | 600 | 0.090 |
Why?
| | Amphetamine-Related Disorders | 1 | 2011 | 36 | 0.090 |
Why?
| | Benzhydryl Compounds | 1 | 2011 | 66 | 0.090 |
Why?
| | Methamphetamine | 1 | 2011 | 55 | 0.090 |
Why?
| | Drug Interactions | 1 | 2012 | 395 | 0.090 |
Why?
| | Pilot Projects | 2 | 2005 | 1592 | 0.080 |
Why?
| | Ligands | 1 | 2012 | 621 | 0.080 |
Why?
| | Central Nervous System Stimulants | 1 | 2011 | 154 | 0.080 |
Why?
| | DNA Fingerprinting | 1 | 2009 | 26 | 0.080 |
Why?
| | Baclofen | 1 | 2009 | 15 | 0.080 |
Why?
| | Genome, Bacterial | 1 | 2009 | 134 | 0.080 |
Why?
| | Psychology | 2 | 2006 | 82 | 0.070 |
Why?
| | Calcium | 1 | 2014 | 1212 | 0.070 |
Why?
| | Intensive Care Units | 1 | 2013 | 735 | 0.070 |
Why?
| | Temperance | 1 | 2007 | 13 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2009 | 321 | 0.070 |
Why?
| | Behavior Therapy | 2 | 2009 | 241 | 0.070 |
Why?
| | Liver | 2 | 2007 | 1842 | 0.070 |
Why?
| | Liver Function Tests | 1 | 2007 | 112 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 394 | 0.070 |
Why?
| | Liver Failure | 1 | 2007 | 91 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2013 | 761 | 0.070 |
Why?
| | Disease Management | 1 | 2010 | 588 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2006 | 130 | 0.060 |
Why?
| | Skull | 1 | 2006 | 129 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 466 | 0.060 |
Why?
| | Esters | 1 | 2006 | 73 | 0.060 |
Why?
| | Carbamazepine | 1 | 2005 | 19 | 0.060 |
Why?
| | Education | 1 | 2005 | 101 | 0.060 |
Why?
| | Saliva | 1 | 2006 | 211 | 0.060 |
Why?
| | History, 20th Century | 1 | 2006 | 294 | 0.060 |
Why?
| | Genomics | 1 | 2009 | 718 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 819 | 0.060 |
Why?
| | Aspartate Aminotransferases | 1 | 2004 | 88 | 0.060 |
Why?
| | Regression Analysis | 1 | 2006 | 997 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2004 | 153 | 0.050 |
Why?
| | Social Support | 1 | 2007 | 584 | 0.050 |
Why?
| | Practice Guidelines as Topic | 3 | 2006 | 1501 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 515 | 0.050 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 235 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 419 | 0.050 |
Why?
| | Survival Analysis | 1 | 2006 | 1269 | 0.050 |
Why?
| | Fatty Acids | 1 | 2006 | 427 | 0.050 |
Why?
| | Minority Groups | 1 | 2005 | 249 | 0.050 |
Why?
| | Aged | 3 | 2014 | 22061 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2006 | 1282 | 0.050 |
Why?
| | Actinomycetales | 1 | 2002 | 2 | 0.050 |
Why?
| | Prospective Studies | 2 | 2005 | 7135 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1203 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2003 | 215 | 0.050 |
Why?
| | Quality of Life | 2 | 2020 | 2688 | 0.050 |
Why?
| | United States Department of Veterans Affairs | 1 | 2005 | 623 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2005 | 527 | 0.040 |
Why?
| | Motivation | 1 | 2005 | 547 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2013 | 14522 | 0.040 |
Why?
| | Health Status | 1 | 2005 | 756 | 0.040 |
Why?
| | Outpatients | 1 | 2003 | 373 | 0.040 |
Why?
| | Risk Factors | 3 | 2013 | 9786 | 0.040 |
Why?
| | Curriculum | 1 | 2005 | 920 | 0.040 |
Why?
| | Time Factors | 2 | 2006 | 6555 | 0.030 |
Why?
| | Reducing Agents | 1 | 2016 | 4 | 0.030 |
Why?
| | Drug Resistance | 1 | 2017 | 165 | 0.030 |
Why?
| | Remission Induction | 1 | 2017 | 274 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 370 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2005 | 1020 | 0.030 |
Why?
| | Oxidants | 1 | 2016 | 109 | 0.030 |
Why?
| | Case Management | 2 | 2006 | 63 | 0.030 |
Why?
| | Sodium Chloride | 1 | 2016 | 137 | 0.030 |
Why?
| | Health Plan Implementation | 2 | 2006 | 137 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 541 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3394 | 0.030 |
Why?
| | Patient Readmission | 2 | 2013 | 653 | 0.030 |
Why?
| | Health Services Accessibility | 3 | 2006 | 903 | 0.030 |
Why?
| | Taste | 1 | 2016 | 216 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1042 | 0.030 |
Why?
| | Rheology | 1 | 2014 | 90 | 0.030 |
Why?
| | Solubility | 1 | 2014 | 232 | 0.030 |
Why?
| | Continuity of Patient Care | 2 | 2006 | 273 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2006 | 569 | 0.030 |
Why?
| | Self Care | 2 | 2006 | 363 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1028 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2006 | 737 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2011 | 64 | 0.020 |
Why?
| | Psychotherapy, Group | 1 | 2011 | 65 | 0.020 |
Why?
| | Chronic Disease | 2 | 2006 | 1720 | 0.020 |
Why?
| | DNA Restriction-Modification Enzymes | 1 | 2009 | 1 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2009 | 32 | 0.020 |
Why?
| | Cohort Studies | 2 | 2013 | 5426 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 460 | 0.020 |
Why?
| | GABA Agonists | 1 | 2009 | 20 | 0.020 |
Why?
| | Food Microbiology | 1 | 2009 | 61 | 0.020 |
Why?
| | Limbic System | 1 | 2009 | 47 | 0.020 |
Why?
| | Multigene Family | 1 | 2009 | 199 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 201 | 0.020 |
Why?
| | Employment | 1 | 2009 | 167 | 0.020 |
Why?
| | Safety | 1 | 2009 | 335 | 0.020 |
Why?
| | Educational Status | 1 | 2009 | 471 | 0.020 |
Why?
| | Medication Adherence | 1 | 2011 | 558 | 0.020 |
Why?
| | Counseling | 1 | 2009 | 386 | 0.020 |
Why?
| | Calibration | 1 | 2006 | 140 | 0.020 |
Why?
| | Pensions | 1 | 2005 | 4 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2005 | 34 | 0.020 |
Why?
| | Public Sector | 1 | 2005 | 17 | 0.020 |
Why?
| | Personality Assessment | 1 | 2005 | 81 | 0.010 |
Why?
| | Combat Disorders | 1 | 2005 | 37 | 0.010 |
Why?
| | Interview, Psychological | 1 | 2005 | 93 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2005 | 305 | 0.010 |
Why?
| | Cross-Sectional Studies | 2 | 2005 | 5075 | 0.010 |
Why?
| | California | 1 | 2005 | 400 | 0.010 |
Why?
| | Disability Evaluation | 1 | 2005 | 285 | 0.010 |
Why?
| | Random Amplified Polymorphic DNA Technique | 1 | 2002 | 3 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 21 | 0.010 |
Why?
| | DNA, Ribosomal | 1 | 2002 | 83 | 0.010 |
Why?
| | Staphylococcus | 1 | 2002 | 74 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3080 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1843 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2005 | 506 | 0.010 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2002 | 524 | 0.010 |
Why?
| | Indians, North American | 1 | 2005 | 601 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 778 | 0.010 |
Why?
| | Age Factors | 1 | 2005 | 3152 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 2057 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3075 | 0.010 |
Why?
|
|
Beresford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|